<DOC>
	<DOC>NCT02566525</DOC>
	<brief_summary>Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorbÂ® device.</brief_summary>
	<brief_title>CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery</brief_title>
	<detailed_description />
	<criteria>Elective, cardiac surgery requiring cardiopulmonary bypass with anticipated duration of &gt;180 minutes Platelet count &lt; 20,000/ uL Body mass index &lt;18 Pregnant women Life expectancy of &lt;14 days End stage organ disease Active infection Undergoing cardiac transplant or ventricular assist device explant, isolated primary coronary artery bypass grafting (CABG) or single valve procedure Contraindication to anticoagulation with heparin Declined informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CytoSorb device</keyword>
	<keyword>Plasma free hemoglobin</keyword>
	<keyword>inflammation</keyword>
	<keyword>extracorporeal bypass</keyword>
</DOC>